Article Details
Retrieved on: 2024-11-28 22:11:14
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses the Phase 2a trial results of CVXGA, a new intranasal COVID-19 vaccine from Blue Lake Biotechnology and CyanVac LLC. Results show strong safety and efficacy, surpassing traditional vaccines. The focus is on RNA vaccines, emphasizing advancement in vaccine technology.
Article found on: pipelinereview.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here